Allergan Drops Development of siRNA Rx for AMD on Poor Phase II Data

The rights to AGN-745, which Allergan originally licensed from Sirna Therapeutics, have been returned to Sirna's parent firm Merck. However, a Merck spokeswoman said that the company has no plans to further develop the drug.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.